Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDATOR: Pre-emptive Daratumumab in Multiple Myeloma
NCT03697655Phase 2Unknown
- Sponsor
- Polish Myeloma Consortium
- Start
- Dec 2018
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daratumumab in multiple myeloma (MM) (4 cohorts), sponsored by Polish Myeloma Consortium. Primary endpoint: Event Free Survival up to 129 weeks. Status: unknown.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03697655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697655.